Jana Ivanidze
Weill Medical College of Cornell University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jana Ivanidze as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:59 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06377371 · Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATEWeill Medical College of Cornell University · recruiting · Meningioma · principal investigator
- Ph4NCT06072807 · Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast CancerWeill Medical College of Cornell University · recruiting · Breast Cancer, Brain Metastases · principal investigator
- Ph2NCT04298541 · Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOCWeill Medical College of Cornell University · withdrawn · Meningioma · principal investigator
- Ph4NCT04081701 · 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.Weill Medical College of Cornell University · recruiting · CNS Tumors, Meningioma, Esthesioneuroblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Dual-[Hypoxia+Proliferation] PET as a Predictive Biomarker in Recurrent GlioblastomaR01CA308323 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · fiscal years 2026 · $655,014 awarded in 2026Same name and institution; not confirmed by an ID
- Somatostatin Receptor 2 Expression in Pituitary Neuroendocrine Tumors as a Basis for PET/MRI guided Subtype Stratification and Radiotherapy PlanningR21CA289111 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · fiscal years 2025 to 2026 · $196,086 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:59 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.J Neurosurg Pediatr · 202150 citationsRCR 3.2
- [Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas.Neuro Oncol · 202427 citationsRCR 5.4
- Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection.J Cancer Res Ther · 201010 citationsRCR 0.3